Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Since then, demand for the glucagon-like peptide 1 has skyrocketed ... The phase 3 trials evaluated tirzepatide 10 mg or 15 mg compared with placebo in patients with or without positive airway ...

Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...

Tirzepatide, a dual glucagon-like peptide 1 (GLP-1 ... In both, the participants randomly received either 10 mg or 15 mg of tirzepatide or placebo once weekly for 52 weeks. At baseline, 65% ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide ... were randomly assigned 1:1 to receive Zepbound (10mg or 15mg; maximum tolerated dose) or placebo injected ...

Tirzepatide (Mounjaro, Eli Lilly) is a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‑1 (GLP‑1) receptor agonist for subcutaneous injection with a ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.

The quest for effective weight loss methods has led to the development of various approaches, including the use of medications. In recent years, peptide-containing medications have gained ...